Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Antibiogram”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7Linked to original sources
PubMed1996

Aerococcus-like organisms: use of antibiograms for diagnostic and taxonomic purposes.

Recently, some Aerococcus-like organisms (ALOs), isolated from urine and blood of elderly patients with urinary tract infection, have been described. In this study ALOs and related taxons were tested for susceptibility by agar diffusion and agar dilution methods to 15 selected antimicrobial agents for diagnostic and taxonomic considerations. ALOs were susceptible to a wide range of antimicrobials including beta-lactams, but resistant to aminoglycosides, sulphonamides, trimethoprim and nalidixic acid. By using tablets containing vancomycin, furazolidone and bacitracin, it was possible to separate ALOs from related taxons. Clustering based on antibiotic susceptibilities showed that there is little similarity between Aerococcus viridans and ALOs.

Anti-Bacterial Agents↗
PubMed2004

Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram.

OBJECTIVE: To evaluate the effect of an antimicrobial management programme on broad-spectrum antimicrobial use and antimicrobial susceptibilities of common nosocomial pathogens at a tertiary-care teaching hospital. METHODS: Review of hospital charts of patients who had been prescribed broad-spectrum antimicrobials 48 h earlier. Recommendations to streamline or discontinue antimicrobials were made based on results of available microbiology data, radiography studies, as well as the working diagnosis at the time of review. The charts were reviewed again on the following day to assess acceptance or rejection of the recommendations. Antimicrobial use, measured as defined daily dose per 1000 patient days (DDD/1000 PD), was determined before and after the antimicrobial management programme was started and was assessed as the mean quarterly use in the six quarters preceding implementation of the programme compared to the most recent six quarters that the programme has been in existence. Antibiotic susceptibilities were obtained from the clinical microbiology laboratory. RESULTS: Compared to the six quarters before the programme, broad-spectrum antibiotic use decreased by 28% (693 DDD/1000 PD to 502 DDD/1000 PD, P = 0.003). Total antifungal agent use decreased by a similar amount, i.e. 28% (144 DDD/1000 PD to 103 DDD/1000 PD, P = 0.02). Total antimicrobial use decreased by 27% (1461 DDD/1000 PD to 1069 DDD/1000 PD, P = 0.0007). Susceptibilities of common nosocomial Gram-negative organisms to commonly prescribed antibiotics did not change significantly over the 3 years of the programme. The rate of methicillin-resistant Staphylococcus aureus increased significantly in the non-intensive care areas of the hospital (P = 0.02) and decreased significantly in the intensive care areas of the hospital (P = 0.009) over the 4 year period from 2000 to 2003. CONCLUSION: Implementation of an antibiotic management programme resulted in substantial reductions in both broad-spectrum and total antimicrobial consumption without having a significant impact on antibiotic susceptibilities of common Gram-negative microorganisms within the institution. The changes in MRSA rate in the non-ICU and ICU settings may reflect infection control measures that were in place during the study period.

Anti-Infective Agents↗
PubMed2001

Comparison of antibiogram, virulence genes, ribotypes and DNA fingerprints of Vibrio cholerae of matching serogroups isolated from hospitalised diarrhoea cases and from the environment during 1997-1998 in Calcutta, India.

This study identified 17 matching serogroups of Vibrio cholerae belonging to serogroups other than O1 and O139 isolated from human cases and from the environment during a concurrent clinical and environmental study conducted in Calcutta, a cholera endemic area. Isolates within these matching serogroups were compared by various phenotypic and genotypic traits to determine if the environment was the source of the organisms associated with the disease. Clinical strains of V. cholerae were resistant to a greater number of drugs and exhibited multi-drug resistance compared with their environmental counterparts. Except for the presence of the genes for the El Tor haemolysin and the regulatory element ToxR in most of the strains of V. cholerae examined, non-O1, non-O139 V. cholerae strains lacked most of the other known virulence traits associated with toxigenic V. cholerae O1 or O139. Restriction fragment-length polymorphism of virulence-associated genes, ribotypes and DNA fingerprints of strains of matched serogroups showed considerable diversity, although some gene polymorphisms and ribotypes of a few strains of different serogroups were similar. It is concluded that despite sharing the same serogroup, environmental and clinical isolates were genetically heterogeneous and were of different lineages.

Blotting, Southern↗
PubMed1990

Antibiogram of staphylococcal strains isolated from milk and milk-products.

A study of the resistance patterns of 248 staphylococcal isolates from milk and milk products to eight antimicrobial agents using the disc method showed that 80 (32.3%) were resistant to sulphafurazole, 75 (30.2%) to penicillin G, 63 (25.4%) to ampicillin, 23 (9.3%) to cloxacillin, 19 (7.7%) to tetracycline, 17 (6.9%) to streptomycin, 14 (5.6%) to erythromycin and 12 (4.8%) to chloramphenicol. One hundred and sixteen (46.8%) of the 248 staphylococcal isolates were sensitive to all the agents tested. A significant percentage (P less than 0.05) of the isolates from raw milk were resistant to erythromycin, sulphafurazole, cloxacillin, penicillin G and streptomycin compared to isolates from fermented milk. The minimum inhibitory concentrations (MIC) as determined by the tube method for isolates resistant by the disc method, were greater than or equal to 16 micrograms for ampicillin in 5 (11.9%) isolates; greater than or equal to 40 micrograms for cloxacillin, 9 (36.0%) and greater than or equal to 12 international units for penicillin G amongst 12 (22.2%) isolates. MIC values of greater than or equal to 40 micrograms were recorded for 9 (90.0%), 9 (69.2%), 8 (73.7%) and 7 (70.0%) isolates to chloramphenicol, streptomycin, erythromycin and tetracycline respectively. The relatively high level of resistance to antimicrobial agents is a reflection of misuse or abuse of these agents in the environment.

Animals↗
PubMed1990

Comparison of in vitro antibiograms of Bacteroides fragilis group isolates: differences in resistance rates in two institutions because of differences in susceptibility testing methodology.

With 120 clinical isolates of the Bacteroides fragilis group, a comparison of rates of resistance to selected antimicrobial agents by using two susceptibility tests was performed in two medical institutions. The broth microdilution method produced MICs significantly lower than those determined by the agar dilution method. With ceftizoxime and cefoxitin, 88 and 18%, respectively, of the MICs were greater than or equal to 2 twofold dilutions apart. These differences in MIC results produced major interpretive discrepancies for ceftizoxime and cefoxitin, whereas no significant differences in resistance rates were noted for clindamycin and metronidazole.

Anti-Bacterial Agents↗
PubMed2004

Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.

The OPTAMA Program is intended to examine typical antimicrobial regimens used in the treatment of common nosocomial pathogens and the likelihood of these regimens attaining appropriate pharmacodynamic exposure in different parts of the world. A 5,000-subject Monte Carlo simulation was used to estimate pharmacodynamic target attainment for meropenem, imipenem, ceftazidime, cefepime, piperacillin-tazobactam, and ciprofloxacin against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Standard dosing regimens from North America were used. Pharmacokinetic parameter variability was derived from existing healthy volunteer data, and MIC data came from the 2002 MYSTIC Program. Ciprofloxacin displayed the lowest target attainment against all bacterial species (41 to 46% for A. baumannii, 53 to 59% for P. aeruginosa, and 80 to 85% for the Enterobacteriaceae). Increasing the dose to 400 mg every 8 h did not significantly increase target attainment against nonfermenters. Piperacillin-tazobactam target attainments were similar to that of ceftazidime against all pathogens. Higher doses of both compounds were needed to achieve better target attainments against P. aeruginosa. Overall, meropenem, imipenem, and cefepime attained the highest probabilities of attainment against the Enterobacteriaceae (99 to 100%). The carbapenems appear to be the most useful agents against A. baumannii (88 to 92%), and these agents, along with higher doses of any of the beta-lactams, would be the most appropriate choices for empirical therapy for P. aeruginosa infection. Given the lack of agreement between percent susceptibility and probability of target attainment for certain antimicrobial regimens, a methodology employing stochastic pharmacodynamic analyses may be a more useful tool for differentiating the most-optimal compounds and dosing regimens in the clinical setting of initial empirical therapy.

Algorithms↗